Suppr超能文献

肝硬化腹水患者发生肝性胸水的危险因素:一项临床队列研究。

Risk Factors for Hepatic Hydrothorax in Cirrhosis Patients with Ascites - A Clinical Cohort Study.

机构信息

Department of Hepatology and Gastroenterology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus, Denmark.

Department of Gastroenterology, Aalborg University Hospital, Aalborg, Denmark.

出版信息

Dig Dis Sci. 2022 Jul;67(7):3395-3401. doi: 10.1007/s10620-021-07134-8. Epub 2021 Jun 30.

Abstract

BACKGROUND

The risk factors for hepatic hydrothorax are unknown.

METHODS

We used data from three randomized trials of satavaptan treatment in patients with cirrhosis and ascites followed for up to 1 year. We excluded patients with previous hepatic hydrothorax or other causes for pleural effusion. The candidate risk factors were age, sex, heart rate, mean arterial pressure, diuretic-resistant ascites, a recurrent need for paracentesis, diabetes, hepatic encephalopathy, International Normalized Ratio, creatinine, bilirubin, albumin, sodium, platelet count, use of non-selective beta-blockers (NSBBs), spironolactone, furosemide, proton pump inhibitors, and insulin. We identified risk factors using a Fine and Gray regression model and backward selection. We reported subdistribution hazard ratios (sHR) for hepatic hydrothorax. Death without hepatic hydrothorax was a competing risk.

RESULTS

Our study included 942 patients, of whom 41 developed hepatic hydrothorax and 65 died without having developed it. A recurrent need for paracentesis (sHR: 2.55, 95% CI: 1.28-5.08), bilirubin (sHR: 1.18 per 10 µmol/l increase, 95% CI: 1.09-1.28), diabetes (sHR: 2.49, 95% CI: 1.30-4.77) and non-use of non-selective beta-blockers (sHR: 2.27, 95% CI: 1.13-4.53) were risk factors for hepatic hydrothorax. Development of hepatic hydrothorax was associated with a high mortality-hazard ratio of 4.35 (95% CI: 2.76-6.97).

CONCLUSIONS

In patients with cirrhosis and ascites, risk factors for hepatic hydrothorax were a recurrent need for paracentesis, a high bilirubin, diabetes and non-use of NSBBs. Among these patients with cirrhosis and ascites, development of hepatic hydrothorax increased mortality fourfold.

摘要

背景

肝性胸水的风险因素尚不清楚。

方法

我们使用了三项随机对照试验中索拉非尼治疗肝硬化和腹水患者的数据,随访时间长达 1 年。我们排除了既往有肝性胸水或其他原因引起胸腔积液的患者。候选风险因素包括年龄、性别、心率、平均动脉压、利尿剂抵抗性腹水、需要反复进行腹腔穿刺术、糖尿病、肝性脑病、国际标准化比值、肌酐、胆红素、白蛋白、钠、血小板计数、非选择性β受体阻滞剂(NSBBs)、螺内酯、呋塞米、质子泵抑制剂和胰岛素的使用。我们使用 Fine-Gray 回归模型和后向选择确定了风险因素。我们报告了肝性胸水的亚分布危险比(sHR)。没有发生肝性胸水的死亡是竞争风险。

结果

我们的研究纳入了 942 例患者,其中 41 例发生了肝性胸水,65 例死亡但未发生肝性胸水。需要反复进行腹腔穿刺术(sHR:2.55,95%CI:1.28-5.08)、胆红素(sHR:每增加 10 μmol/l 增加 1.18,95%CI:1.09-1.28)、糖尿病(sHR:2.49,95%CI:1.30-4.77)和不使用非选择性β受体阻滞剂(sHR:2.27,95%CI:1.13-4.53)是肝性胸水的风险因素。发生肝性胸水与高死亡率相关(危险比:4.35,95%CI:2.76-6.97)。

结论

在肝硬化和腹水患者中,肝性胸水的风险因素是需要反复进行腹腔穿刺术、高胆红素、糖尿病和不使用 NSBBs。在这些肝硬化和腹水患者中,发生肝性胸水使死亡率增加了四倍。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验